Brought to you by 
Biovail buys Valeant in $3.3bn reverse merger
17 May 2013
Executive Summary
Biovail Corp. has agreed to acquire Valeant Pharmaceuticals International in a reverse merger valued at $3.3bn that will build a specialty pharma company with projected revenues of $1.75bn. Valeant shareholders will receive $43.23--consisting of $16.77 in cash and 1.7809 in Biovail shares for each Valeant share they own. Biovail will have a 50.5% stake in the combined company, and Valeant owns the remainder.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
- Payment Includes Stock
- Reverse Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biovail buys Valeant in $3.3bn reverse merger
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice